Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Increase in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 446,500 shares, a growth of 92.6% from the October 15th total of 231,800 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily volume of 6,030,000 shares, the short-interest ratio is currently 0.1 days.

Virax Biolabs Group Trading Down 4.7 %

Shares of Virax Biolabs Group stock traded down $0.09 during trading on Friday, hitting $1.81. The stock had a trading volume of 74,772 shares, compared to its average volume of 2,221,239. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00. The business’s 50-day moving average is $2.19 and its 200 day moving average is $1.86.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.